GlassScriptPhysician profile
Kathryn M Hinderer
NPI 1124245352
$2,841.23
in general payments reported to CMS, 2019-2025
27 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $154 · 2021: $413 · 2022: $696 · 2023: $401 · 2024: $347 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,109.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $889.51 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $424.72 | 2019-2025 | |
| Amgen INC. | $304.46 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $217.27 | 2022-2025 | |
| Lilly USA, LLC | $212.96 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $210.82 | 2019-2023 | Veozah |
| Merck Sharp & Dohme LLC | $70.56 | 2020-2023 | Vaxelis, M-M-R II, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $54.32 | 2022-2023 | |
| Exact Sciences Corporation | $51.74 | 2024-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $49.11 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.19 | 2020-2024 | Xifaxan |
| Avanir Pharmaceuticals, INC. | $37.09 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $32.17 | 2021 | |
| Harmony Biosciences LLC | $26.69 | 2024 | |
| Amarin Pharma, INC. | $24.72 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24.37 | 2023 | Freestyle Libre 3 |
| Mayne Pharma Commercial LLC | $21.88 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.40 | 2022 | |
| Ibsa Pharma INC. | $16.56 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.22 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.98 | 2025 | Caplyta |
| Ars Pharmaceuticals Operations, INC. | $14.94 | 2025 | Neffy |
| Organon LLC | $14.70 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $13.27 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.13 | 2021 | |
| Allergan, INC. | $11.47 | 2020 | |
| Eisai INC. | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Hinderer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.